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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with an overall 5-year
survival rate of less than 8%. New evidence indicates that PDAC cells release pro-inflammatory metabolites
that induce a marked alteration of normal hematopoiesis, favoring the expansion and accumulation of
myeloid-derived suppressor cells (MDSCs). We report here that PDAC patients show increased levels of both
circulating and tumor-infiltrating MDSC-like cells.
Methods: The frequency of MDSC subsets in the peripheral blood was determined by flow cytometry in three
independent cohorts of PDAC patients (total analyzed patients, n = 117). Frequency of circulating MDSCs was
correlated with overall survival of PDAC patients. We also analyzed the frequency of tumor-infiltrating MDSC
and the immune landscape in fresh biopsies. Purified myeloid cell subsets were tested in vitro for their T-cell
suppressive capacity.
Results: Correlation with clinical data revealed that MDSC frequency was significantly associated with a shorter
patients’ overall survival and metastatic disease. However, the immunosuppressive activity of purified MDSCs was
detectable only in some patients and mainly limited to the monocytic subset. A transcriptome analysis of the
immunosuppressive M-MDSCs highlighted a distinct gene signature in which STAT3 was crucial for monocyte
re-programming. Suppressive M-MDSCs can be characterized as circulating STAT3/arginase1-expressing CD14+ cells.
Conclusion: MDSC analysis aids in defining the immune landscape of PDAC patients for a more appropriate diagnosis,
stratification and treatment.
Keywords: Myeloid-derived suppressor cells (MDSC), Pancreatic ductal adenocarcinoma (PDAC), Innate immunity, Tumor-
associated immunosuppression, Tumor progression
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Background
Over the last thirty years, pancreatic ductal adenocar-
cinoma (PDAC) worldwide incidence has increased
significantly and PDAC ranks the fourth leading cause
of cancer death with a 5-year survival time of less than
8% [1]. Despite many new treatments, including im-
mune modulation, pancreatic cancer remains highly
resistant to therapy [2, 3]. The presence of the highest
degree of desmoplasia among all solid tumors and the
occurrence of a chronic inflammation endorse a crit-
ical role for tumor microenvironment on pancreatic
carcinogenesis [4, 5]. In preclinical models, by releasing high
amounts of growth factors such as granulocyte colony-
stimulating factor (G-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF), pancreatic tumor
cells activate an abnormal myelopoiesis that promotes
the recruitment of a heterogeneous population of mye-
loid cells characterized by a strong immunosuppressive
activity [6, 7]. These cells are termed myeloid-derived
suppressor cells (MDSCs) [8] and their accumulation,
in the blood and at the tumor site, has been associated
with advanced tumor stage and unfavorable prognosis
in several human malignancies [9].
The main feature of MDSCs is the ability to switch
off adaptive and innate immune responses [10]. In-
deed, MDSCs are able to release both reactive oxygen
species (ROS) and reactive nitrogen species (RNS),
which inhibit T cells fitness, proliferation and migra-
tion within the tumor microenvironment; MDSCs
deplete essential metabolites by activating key enzymes
such as arginase-1 (ARG1) and indoleamine 2,3-dioxy-
genase 1 (IDO1), which are capable of reducing L-
arginine and L-tryptophan availability, respectively. In
addition, MDSCs induce T cell tolerance through the
expression of inhibitory receptors such as the
programmed death-ligand 1 (PD-L1) and the cytotoxic
T-lymphocyte antigen 4 (CTLA-4) receptors, as well as
they sustain the development of regulatory T cells
(Treg) through the CD40 engagement in presence of
inteleukin-10 (IL-10) and transforming growth factor beta
(TGFβ) [11]. All these immunosuppressive mechanisms
are the result of altered signaling pathways leading to
induction of transcriptional factors such as the nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-κB) [12], the CCAAT-enhancer-binding proteins (c/
EBP)-β [13] and members of the signal transducer and
activator of transcription (STAT) family, like STAT3 [14].
Besides immune regulation, MDSCs favor tumor progres-
sion also by non-immune properties, promoting tumor
angiogenesis and vasculogenesis as well as cancer cell
stemness, aggressiveness and invasiveness [11].
In mice, MDSCs were classically identified as CD11b+Gr-
1+ cells and divided into two main subgroups: polymorpho-
nuclear (PMN)-MDSCs (CD11b+Ly6G+Ly6Clo cells) and
monocytic (M)-MDSCs (CD11b+Ly6C+Ly6G− cells)
[6]. In humans instead, three major MDSC subsets
have been identified: PMN-MDSCs, M-MDSCs and
“early-stage MDSCs” (e-MDSC) [15]. Since human
MDSCs display surface markers shared with normal
myeloid cell subsets (such as CD14, CD15, and CD33)
and exhibit an intrinsic heterogeneity and plasticity, it is
mandatory to integrate the phenotypical characterization
with functional assays demonstrating their authentic
immunosuppressive functions [15].
Here we applied standardized flow cytometry methods
to distinguish and enumerate circulating MDSCs in both
whole blood (WB) and frozen PBMCs obtained from three
independent cohorts of PDAC patients; additionally, we
analyzed the frequency of tumor-infiltrating MDSC and
the immune composition in freshly isolated biopsies.
Finally, we tested the immunosuppressive functions of
circulating, purified MDSCs by evaluating their ability to
control in vitro proliferation of activated T cells. Since
only the M-MDSC subset showed robust inhibitory
properties, we further exploited their transcriptomic
profile with the aim at identifying novel biomarkers and
specific molecular pathways.
Material and methods
Human samples collection
Peripheral blood samples were prospectively collected
from three independent cohorts of patients with different
stages of pancreatic ductal adenocarcinoma admitted at
the Unit of General and Pancreatic Surgery of the Azienda
Ospedaliera Universitaria Integrata of Verona before sur-
gical resection or Healthy Donors (HD). Clinic-pathologic
features of patients were reported in Tables 1 and 2 and
Table 1 Clinical characteristics of the study population
Patients Cohort (n = 29)
Gender
Male (%) 55.2
Female(%) 44.8
Age (Range) 66 (48–85)
Stage
IIA-IIB (%) 48.3
III (%) 51.7
IV(%) 0.0
Tumor site
Head 86.2
Body 10.3
Tail 3.5
Multi localized 0.0
The total number of cases, the male/female percentage, the mean age (years)
with minimum and maximum value (range), stage and tumor localization of
the analyzed cohort of PDAC patients
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included age, gender, tumor location and TNM stage. No
subject had a prior history of cancer or was undergoing
therapy at the time of sample collection. BM aspirates
were subjected to lysis to remove red blood cells, with a
hypotonic solution of ammonium chloride. Cells were
plated (2 × 106 cells/well) into a 24-well tissue culture
plate (BD, Franklin Lakes, NJ, USA) in IMDM (Lonza,
Visp, Switzerland) supplemented with with 10% FBS
(Euroclone, Milano, Italy), 100 U/ml penicillin/strepto-
mycin (Euroclone, Milano, Italy), β-mercaptoethanol
(Sigma-Aldrich, Milan, Italy) and 10mM HEPES (Euro-
clone, Milano, Italy) in presence of 40 ng/ml of G-CSF
and GM-CSF (Miltenyi Biotec) for 4 days at 37 °C, 8%
CO2, obtaining BM-MDSC as previously reported [16].
Human proliferation assay
PBMCs were isolated from leukocyte-enriched buffy coats
from healthy volunteers (Transfusion Center, University
and Hospital Trust of Verona, Verona, Italy) by Ficoll-
Hypaque (GE Healthcare, Uppsala, Sweden) gradient cen-
trifugation. PBMCs were then counted, frozen at − 80 °C
and stored in liquid nitrogen. PBMCs were recovered,
washed in IMDM medium (Lonza, Visp, Switzerland), sup-
plemented with 10% FBS (Euroclone, Milano, Italy), 100 U/
ml penicillin/streptomycin (Euroclone, Milano, Italy), β-
mercaptoethanol (Sigma-Aldrich, Milan, Italy) and 10mM
HEPES (Euroclone, Milano, Italy), resuspended at a final
concentration of 107 cells/ml in PBS and stained with
1 μM as final working concentration of CellTrace Violet
stock solution (Thermo Fisher Scientific, Waltham, MA,
USA), followed by 5min’ incubation at 37 °C, protected
from light. Labelled “target” PBMCs were stimulated with
coated 0.6 μg/ml anti-CD3 (clone OKT-3, eBioscience,
Thermo Fisher Scientific, Waltham, MA, USA) and 5 μg/
ml soluble anti-CD28 (clone CD28.2, eBioscience, Thermo
Fisher Scientific, Waltham, MA, USA) for 4 days and co-
cultured with “effectors” M-MDSCS (CD14+ cells) or
PMN-MDSC (CD66b+ cells) cells at 0.5:1, 1:1, 3:1, 6:1 ratio
(effector:target) in 384 flat bottom well plates (BD, Franklin
Lakes, NJ, USA). Cell cultures were incubated at 37 °C and
8% CO2 in arginine and glutamine–Free-RPMI (Biochrom
AG, Berlin, Germany), supplemented with 2mML-glu-
tamine (Euroclone, Milano, Italy), 150 μM arginine (Sigma-
Aldrich, St. Louis, MO, USA), 10% FBS (Superior, Merck,
Darmstadt, Germany), 10 U/ml penicillin and streptomycin
(Euroclone, Milano, Italy), and 0.1mM HEPES (Euroclone,
Milano, Italy). At the end of the culture, cells were stained
with PE-Cy7 conjugated anti-CD3 (UCHT1, eBioscience,
Thermo Fisher Scientific, Waltham, MA, USA), and Cell-
Trace signal of gated lymphocytes was analyzed. Tru-
Count™ tubes (BD, Franklin Lakes, NJ, USA) were used to
determine the absolute cell number of CD3+ cells in the
samples. Data were analyzed by FlowJo software (Tree Star,
Inc. Ashland, OR, USA).
Human cell preparation and flow cytometric analysis
Blood was collected into EDTA-treated tubes (BD Bio-
sciences, NJ, USA) and processed fresh. For each
donor, 450 μL of whole blood or 106 frozen PBMCs
were taken for MDSC characterization by flow cytometry.
Sample tubes were washed in phosphate-buffered saline
(PBS), incubated with Fc receptor (FcR) Blocking reagent
(Miltenyi Biotec) for 10min at 4 °C to saturate FcR and
then stained with fluorochrome-conjugated antibodies
(Additional file 1: Supplementary methods). For tumor-
infiltrating leukocytes evaluation, tumor biopsies were
minced and incubated for 2 h at 37 °C with shaking with
an enzymatic cocktail. Normal tissues were detected by
Table 2 Clinical characteristics of the study population
Cohort_1 (n = 21) Cohort_2 (n = 23) Cohort_3 (n = 73)
Gender
Male (%) 61.9 30.4 53.4
Female(%) 38.1 69.6 46.6
Age (Range) 67 (52–79) 67 (47–84) 65 (40–82)
Stage
I-II (%) / / 28.7
III (%) 57.1 56.5 39.7
IV(%) 42.9 43.5 31.6
Tumor site
Head 43.3 26.1 64.7
Body 29.0 47.8 19.1
Tail 19.0 17.4 6.8
Multi localized 8.7 8.7 9.4
The total number of cases, the male/female percentage, the mean age (years) with minimum and maximum value (range), stage and tumor localization of the
three cohorts of PDAC patients. In each cohort, PDAC patients were compared to a cohort of age- and gender-matched healthy donors
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pathological analysis and isolated from patient biopsies.
5 × 105 cells were washed with PBS supplemented with 2
Mm EDTA, incubated with FcR Blocking reagent (Milte-
nyi Biotec) for 10min at 4 °C and then stained with
fluorochrome-conjugated antibodies (Additional file 1:
Supplementary methods).
RNA isolation and gene expression
Total RNA was isolated using TRIzol reagent (Life tech-
nology, CA, USA) and RNA integrity assessed using
Agilent-2100-Bioanalyzer (Agilent Technologies, CA,
USA). RNA from human CD14+ cells was further puri-
fied with RNeasy MinElute Cleanup kit (Qiagen, Venlo,
Netherlands) and cDNA was synthesized and amplified
from total purified RNA with RETROscript® (Life tech-
nology, CA, USA). All the samples were hybridized to
Affymetrix U133 PLUS 2.0 arrays and scanned with an
Affymetrix GCS 3000 7G scanner.
Statistical analysis
All statistical analysis was carried out using SigmaPlot
(Systat Software) and R/Bioconductor. For statistical
comparison of two groups, non-parametric Mann-
Whitney Wilcoxon test was used. Data are shown as
mean ± SD or mean ± SEM as indicated in the figures
legends. Receiver operator characteristic (ROC) analysis
was performed to determine the performance of MDSC
percentage in distinguishing patients with metastatic
carcinoma. The optimal cutoff threshold for MDSC
percentage was obtained based on the maximization of
the Youden’s statistics J = sensitivity+specificity+ 1 by
using an R-based software as described [17]. Statistical
analyses were performed using SPSS Statistics 22 (IBM
Corporation, Somers, NY, USA), GraphPad Prism soft-
ware program (version 6.0; GraphPad Software, San
Diego, CA), and the statistical language R.
Results
The frequency of tumor-infiltrating T cells inversely
correlates with the presence of PMNs and M-MDSCs
The immune composition of PDAC has been shown to
have prognostic implications, with high number of
CD8+ T lymphocytes associated with good outcome
while accumulation of myeloid cells with poor progno-
sis [18, 19]. However, our knowledge on the immune
heterogeneity of the PDAC microenvironment is still
limited and need to be further investigated. To dissect
this complexity, using a multicolour flow cytometry ap-
proach, we analysed infiltrating leukocytes isolated
from 29 tumor samples from treatment-naïve PDAC
patients (Table 1) and 5 normal pancreatic biopsies,
obtained from tumor-free tissues of some patients.
Among alive CD45+ cells, we focused on T lymphocytes
(CD3+ cells), effector T lymphocytes (CD3+CD8+ cells),
helper T lymphocytes (CD3+CD4+ cells), regulatory T
lymphocytes (CD3+CD4+ CD25+FoxP3+ cells, Tregs), B
lymphocytes (CD3−CD19+ cells), regulatory B cells
(CD3−CD19+CD25+FoxP3+ cells, Bregs), myeloid-dendritic
cells (CD11b+CD11c+HLA-DR+ cells, DCs), plasmacitoid
DCs (CD11b+CD11c−CD123+, pDCs), macrophages (CD
14+HLA-DR+CD68+CD206+ cells), granulocytes (PMNs,
CD14−CD15+CD11b+ cells) as well as two MDSC subsets:
e-MDSCs (Lin−HLA-DR−CD11b+CD33+ cells) and M-
MDSCs (CD14+HLA-DR−/lo cells) (Additional file 1:
Figure S1). Notably, we found that PDAC tissues have
a higher CD45+ cell infiltrate than their normal counter-
part, likely reflecting the ability of the tumor or surround-
ing stroma to release soluble factors attracting immune
cells [20, 21] (Fig. 1a). Among the CD45+ cells, we identi-
fied a high frequency of several myeloid cells, such as
PMNs, MDSCs and macrophages (Fig. 1b) and several T
cell subsets, supporting the current hypothesis that PDAC
is not an immune “desert” [22, 23]. While we did not find
expansion in Bregs (0.052 ± 0.012) and pDCs (0.073 ±
0.018), we observed a higher frequency of several myeloid
cells, such as PMNs (28.89 ± 4.693), M-MDSCs (0.969 ±
0.167), e-MDSC (1.235 ± 0.198) and macrophages (8.832 ±
2.265) and Tregs (1.092 ± 0.196) (Fig. 1b), supporting the
concept that PDAC is a tumor with an immune-hostile
tumor microenvironment [24]. Indeed, a significant inverse
correlation between T cell numbers with either PMN or
M-MDSCs, but not with macrophages and e-MDSCs,
could be detected (Fig. 1c), which is in line with recent re-
ports. Of note, a significant inverse correlation between
both PMNs and B cells, as well as between PMNs and
different T cell subsets including effectors T cells, helper T
cells and Tregs emerged (Additional file 1: Figure S2).
Interestingly, we identified a significant direct linear correl-
ation between T cells and Tregs as well as a trend between
M-MDSCs and Tregs (Additional file 1: Figure S2).
Collectively, these results suggest that accumulation of
myeloid cells, such as MDSCs, in PDAC is detrimental for
T cell infiltration.
PDAC patients exhibit a significant increase in circulating
MDSCs
Preclinical data suggest that PDAC effects on the immune
system are not limited to local microenvironment but
might cause systemic alterations, fuelling an “emergency”
myelopoiesis that favours the accumulation of circulating
MDSCs [13]. To assess systemic changes in PDAC
patients, we evaluated the presence of different MDSC
subsets in the peripheral blood, following recently pub-
lished guidelines [25]. Three independent patient cohorts
(Table 2) were enrolled to define the MDSC baseline at
diagnosis: the first cohort comprised 21 PDAC patients
(stage III-IV) and 8 age- and sex-matched healthy donors
(HD) (Fig. 2a), the second cohort comprised 23 PDAC
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patients (stage III-IV) and 9 HDs (Fig. 2b); the last cohort
consisted of 73 PDAC patients, including resectable (stage
I-II, n = 21) and non-resectable (stage III-IV, n = 52) tu-
mors and 28 HDs (Fig. 2c). MDSC analysis was performed
using both fresh whole blood (WB) cells (Fig. 2a-b) and
frozen peripheral blood mononuclear cells (PBMCs)
(Fig. 2c). In fresh WB we analyzed the frequency of mono-
cytes (CD14+CD15−CD11b+) and granulocytes (PMNs,
CD15+CD14−CD11b+) as well as the presence of MDSC1
(CD14+IL-4Rα+), MDSC2 (CD15+IL-4Rα+), MDSC3
(Lin−HLA-DR−CD33+) and MDSC4 (CD14+HLA-DR−/low)
subsets (Additional file 1: Figure S3). Among frozen
PBMCs, we only discriminate monocytic (MDSC1 and
MDSC4) and early-stage (MDSC3) MDSCs; the assessment
of PMN-MDSCs is not accurate and probably even
misleading, since granulocytes (including PMN-MDSCs)
are typically lost during freezing/thawing procedure. We
detected a significant increase in circulating M-MDSC sub-
sets (MDSC1 and MDSC4) in PDAC patients compared to
the control group in the three independent analyses (for
CD14+IL-4Rα+ cells, median value 0.19% vs. 0.57%, p <
0.001 in the first cohort, 0.18% vs. 0.59%, p < 0.001 in the
second cohort and 2.2% vs. 4.3%, p = 0.002 in the third
cohort; for CD14+HLA-DR−/low cells, median value 0.19%
vs. 0.31%, p = 0.033 in the first cohort, 0.08% vs. 0.32%, p =
0.042 in the second cohort and 1.78% vs. 3.25%, p < 0.001
in the third cohort). Moreover PMN-MDSC subset
(MDSC2) was significantly increased in PDAC patients:
CD15+IL-4Rα+ cells, median value 1.53% vs. 4.89%, p =
0.006 in the first cohort, 1.89% vs. 6.78%, p < 0.001 in the
second cohort. Interestingly, PDAC patients showed an
increased frequency in WB of both monocytes and granulo-
cytes compared to HDs: for monocytes, median value was
0.94% vs. 3.15%, p < 0.001 in the first cohort, 0.98% vs.
3.95%, p < 0.001 in the second cohort; for granulocytes,
median value 44.82% vs. 56.23%, p = 0.006 in the first
cohort, 47.89% vs. 62.45%, p < 0.001 in the second cohort.
Finally, we did not observe any alteration in circulating e-
MDSCs (MDSC3) between HDs and cancer patients in any
of the analysed cohorts.
To determine whether increased MDSC subsets could
predict patient outcome, we analysed PDAC cohort 1
and 2 since these groups were homogeneously composed
by poorly differentiated tumors (G3 and G4). The
MDSC analysis was performed using the same sampling
protocol based on fresh WB. We discovered that only
MDSC2 frequency higher than optimal cutoff threshold
(9.156%) was significantly associated with a shorter
patient’s median overall survival (OS) (Fig. 3a) while the
other analyzed MDSC subsets (MDSC1, MDSC3 and
MDSC4) did not show any correlation with patients
survival (Additional file 1: Figure S4). Moreover, a higher
Fig. 1 Immune characterization of PDAC tumor microenvironment. a Leukocytes infiltration (CD45+ cells) in normal pancreas (n = 5) and PDAC
tissue (n = 29) biopsies. Statistical analysis was performed by ANOVA test. b Immune populations abundance (% of CD45+ cells) in PDAC tissues. c
Correlation between tumor-infiltrating T cells with either macrophages, PMNs, M-MDSCs or e-MDSCs within PDAC tissues. Correlation analysis was
performed by Spearman’s rank correlation
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MDSC2 percentage is found in metastatic patients (p =
0.064, Fig. 3b) and significantly discriminated patients
with metastatic disease with AUC value of 0.633 (p =
0.011, Fig. 3c) and an optimal cutoff threshold value of
9.156% (sensitivity of 57.1% (95% CI = 32.6–78.6%) and a
specificity of 85.7% (95% CI = 65.4–95%)). In particular,
18 out of 24 (75%) patients with MDSC2 percentage
lower than the identified cutoff did not present distant
cancer dissemination whereas only 6 out of 24 (25%)
patients presented clinically detectable metastases.
Conversely, 8 out of 11 (73%) patients with MDSC2
percentage higher than the identified threshold pre-
sented metastases while 3 out of 11 (27%) patients had
no metastasis (Fig. 3d). Starting from these premises, we
evaluated the power of MDSCs from frozen PBMCs in
discriminating patients with metastatic disease. Only
MDSC4 frequency was able to significantly discriminate
non-metastatic versus metastatic tumors (Fig. 3e) with
AUC value of 0.705 (p = 0.017) (Fig. 3f) and a calculated
threshold of 3.505% (sensitivity of 70% (95% CI = 39.7–
Fig. 2 Blood-circulating MDSC enumeration in PDAC patients. a-b Flow cytometry analysis of circulating myeloid cells in whole blood of two
independent cohorts of PDAC patients (b PDAC n = 21, HD = 8; c PDAC n = 23, HD = 9): monocytes (CD14+CD15−), MDSC1 (CD14+IL-4Rα+),
MDSC4 (CD14+HLA-DRlow/−), granulocytes (CD15+CD14−), MDSC2 (CD15+IL-4Rα+) and MDSC3 (LIN−HLA-DR−CD33+SSChigh). c Flow cytometry
analysis of circulating M-MDSCs (MDSC1, CD14+IL-4Rα+; MDSC4, CD14+HLA-DRlow/−) and e-MDSCs (MDSC3, LIN−HLA-DR−CD33+SSChigh) in PDAC
patients (n = 73) compared to healthy donors (HD; n = 28). M-MDSC percentages were evaluated on frozen PBMCs, whereas e-MDSCs on the
whole blood. Statistical analysis was performed by ANOVA test
Trovato et al. Journal for ImmunoTherapy of Cancer           (2019) 7:255 Page 6 of 16
89.2%) and a specificity of 78.9% (95% CI = 56.7–91.5%)).
In fact, 15 out of 18 (83.3%) patients with MDSC4
percentage lower than the identified cutoff did not show
metastases, whereas only 3 out of 18 (16.6%) patients
present a metastatic disease; on the contrary, 7 out of 11
(63.6%) patients with MDSC4 percentage higher than
the identified threshold had metastases, and 4 out of 11
(36.4%) patients did not show metastases (Fig. 3g).
Collectively, these data suggest that MDSC percentage
might be a valid prognostic biomarker of advanced
disease in PDAC patients, even though the selection of
the biomarker is strictly dependent on sampling: when
the analysis is performed on cryopreserved PBMCs,
MDSC4 levels could identify patients with metastatic
disease, whereas MDSC2 frequency could stratify
patients with metastases when the analysis is performed
on fresh blood samples.
Circulating monocytes from PDAC patients induce a
stronger T-cell suppression compared to PMNs
resembling effective M-MDSCs
We then evaluated in vitro the immunosuppressive
properties of PMNs (isolated as CD66b+ cells) and
monocytes (isolated as CD14+ cells) freshly purified from
blood samples of the second PDAC patients cohort (n =
10) to confirm their MDSC-associated functional activity
(cell purity was above 95% after cell isolation, Fig. 4a).
Isolated cells were co-cultured in presence of activated,
cell trace-labelled allogeneic PBMCs for 4 days. As re-
ported in Fig. 4b, at the highest T cells:myeloid cells cell
Fig. 3 Prognostic potential predictive role of MDSCs in PDAC patients. a Kaplan–Meier curves for OS by significant MDSC2 cutoff frequency in
fresh whole blood samples. b MDSC2 percentages in non-metastatic and metastatic PDAC patients. Mean and 95% confidence interval are
plotted. Statistical analysis was performed by ANOVA test. c Receiver operator characteristic (ROC) curve for MDSC2 percentage in metastatic
disease prediction. d Waterfall plot of optimal dichotomization; blue and red bars represent cases with correct or wrong classification,
respectively. e MDSC4 percentage in non-recurrent and recurrent PDAC patients. Mean and 95% confidence interval are plotted. Statistical
analysis was performed by ANOVA test. f Receiver operator characteristic (ROC) curve for MDSC4 percentage in metastatic disease prediction. g
Waterfall plot of optimal dichotomization, blue and red bars represent cases with correct or wrong classification, respectively
Trovato et al. Journal for ImmunoTherapy of Cancer           (2019) 7:255 Page 7 of 16
Fig. 4 Circulating monocytes from PDAC patients are able to restrain T cell proliferation in vitro. a Freshly isolated PMNs (CD66b+ cells, orange
box) and monocytes (CD14+ cells, blue box) from PDAC patients analysed by flow cytometry and haematoxylin-eosin staining. b Functional assay
reflecting the different ability of PMNs and monocytes to affect T cells proliferation when co-cultured in vitro with CD3/CD28-activated-PBMCs at
different ratios. All values are normalized on the activated PBMCs in the absence of myeloid cells (grey bar) and reported as percentage of Cell
Trace+CD3+ cells. Statistical analysis was performed by ANOVA test. c Functional assay performed (at 1:3 ratio of PBMCs:CD14+ cells) on
monocytes of PDAC patients (n = 26) compared to HDs (n = 8), reported as percentage of CD3+ proliferating cells (right panel) and graphed as
proliferation peaks of Cell Trace+CD3+cells after the co-culture (left panel). Among all PDAC patients, “Suppressive CD14+ cells” (blue) and “Non-
suppressive CD14+ cells” (red) were grouped based on the quantitative analysis of the in vitro immunosuppressive function. Statistical analysis
was performed by ANOVA test. d Different ability of suppressive and non-suppressive monocytes to limit CD3+ T cell proliferation at different cell
ratios. Statistical analysis was performed by ANOVA test. e Pearson correlation between MDSC4 and MDSC1 among CD14+ cells of PDAC patients.
f Pro-metastatic potential of suppressive CD14+ cells. Statistical analysis was performed by Pearson Chi-Square test
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ratio (1:6) both myeloid cell subsets showed suppressive
activity, whereas only monocytes were able to restrain T
cell proliferation at lower cell ratio (i.e. at 1:1 ratio; p =
0.021 myeloid cells/PBMCs), in agreement with previous
preclinical reports [6, 26]. Therefore, these data suggest
that in PDAC patients, the per cell based suppressive
capacity of neutrophils is lower than the one of mono-
cytes, as it was already observed for other tumors [27].
We further validated the immunosuppressive activity
of CD14+ cells purified from PDAC patients (n = 26)
enrolled in the third cohort. Based on this analysis we
stratified PDAC patients into two sub-groups: “suppres-
sive PDAC” (n = 6, blue plots), whose monocytes were
able to arrest T cells proliferation at different cell ratios
(starting from 1:3 ratio of PBMCs:CD14+ cells), and
non-suppressive/poorly suppressive PDAC (n = 20, red
plots; hereafter referred as “non-suppressive PDAC”), in
which CD14+ cells did not show any inhibitory proper-
ties similarly to HD-derived monocytes (n = 8, black
plots) (Fig. 4c-d). We found that the presence of either
suppressive or non-suppressive CD14+ cells did not
correlate with any MDSC subsets: M-MDSC frequency
(i.e. suppressive vs. non-suppressive: MDSC1/CD14+
cells median value 74.66 vs. 69.90, p = 0.53; MDSC4/
CD14+ cells median value 5.78 vs. 4.09, p = 0.11) and the
mean fluorescence intensity of IL-4Rα expressed on
MDSC1 cells (i.e. suppressive vs. non-suppressive: me-
dian value 368.83 vs. 286.19, p = 0.44) did not correlate
with immunosuppressive activity, as well. Moreover, we
did not identify any clinical parameter able to discrimin-
ate the suppressive and not suppressive group of patients
(i.e. those with immunosuppressive or not suppressive
CD14+ cells). In fact, cell counts were not significantly
different between the analyzed groups (suppressive vs.
non-suppressive): WBE [109/L] median value 5.89 vs.
6.08, p = 0.76; neutrophils [109/L] median value 3.845 vs.
3.749, p = 0.86; monocytes [109/L] median value 0.265
vs. 0.344, p = 0.16; lymphocytes [109/L] median value
1.58 vs. 1.65, p = 0.58. Interestingly, we observed an
inverse correlation comparing the frequency of MDSC1
and MDSC4 among monocytes (Fig. 4e), which allowed
to distinguish the 80% of suppressive PDAC samples
towards non-suppressive samples: suppressor mono-
cytes showed simultaneously discrete amount of both
MDSC-1 (MDSC1/CD14+ > 70%) and MDSC-4 (MDSC4/
CD14+ > 0.2%), suggesting that both cell populations play
a critical role in promoting a functional inhibition of T cell
proliferation. Furthermore, the presence of suppressive
CD14+ cells were able to significantly cluster metastatic
versus non-metastatic patients: in fact, 11 out of 17
patients that exhibited suppressive monocytes (64.7%)
presented a metastatic disease while this was found only
in 8 out of 29 patients with non-suppressive monocytes
(27.6%). Conversely, only 6 out of 17 patients presented a
suppressive profile (35.3%) whereas 21 out of 29 patients
with a non-suppressive profile (72.4%) exhibited a non-
metastatic disease (Fig. 4f). Collectively, these data high-
light that suppressive monocytes have a pro-metastatic
potential.
Immunosuppressive PDAC-derived CD14+ cells mainly
activate a STAT3/arginase 1 axis
In order to define the molecular network relevant for
CD14+ cell immunosuppression, we performed a genome-
wide mRNA expression profiling on purified monocytes
isolated from 3 suppressive and 4 non-suppressive PDAC
patients. First of all, we compared the gene profiles of
PDAC-derived monocytes against three independent
public datasets of normal circulating CD14+ cells isolated
from HDs (GSE60601, GSE64480 and GSE13899) demon-
strating a specific cancer-related signature, as the
hierarchical gene clustering revealed different patterns of
expression between the two groups (Additional file 1:
Figure S5A). Indeed, by using the gene set enrichment
analysis (GSEA) of hallmarks of cancer, the differentially
expressed genes were enriched in categories involved
in: TNFα signaling via NF-κB, inflammatory response,
IL6 JAK/STAT3 signaling and apoptosis categories
(Additional file 1: Figure S5B). These results are in agree-
ment with our recent findings [12] and indicate how
cancer cells alter the normal monopoiesis favouring the
development of CD14+ cells with cancer-related imprint.
To elucidate further this cancer-driven reprogramming,
we compared the gene profile of suppressive towards
non suppressive PDAC monocytes by clustering genes
according to their expression levels, demonstrating
that immunosuppressive monocytes had a distinctive
gene signature (Fig. 5a). The comparative analysis
identified differences in the expression of genes in-
volved in metabolism, cell cycle, signaling and struc-
tural components (Fig. 5b). Considering the structural
constituents category, suppressive CD14+ cells showed
a greater expression in FBN2, TSPAN16, LEPR, CLTA and
CD163 that are normally associated with classic mono-
cytes. In particular, CD163 expression is strongly regu-
lated by IL-6 and IL-10 that are two of the main
inflammatory mediators in PDAC patients’ sera [12, 21].
Moreover, the CD163 cleaved form (sCD163), released by
monocytes/macrophages, was reported to inhibit T cell
proliferation, underlying its potential involvement in
immune evasion [28]. Suppressive monocytes showed also
an altered cell cycle-associated gene signature, as well as a
complex signaling-related gene enrichment. Among cell
cycle cluster, we found the expression of CASP2, recently
described as a regulating key of myeloid progenitor differ-
entiation [29]; AKAP9, involved in c-AMP-dependent
suppression on LPS-activated macrophages and NLRP1,
described to impair T cell responses [30]. In the signaling
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Fig. 5 (See legend on next page.)
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category, we identified the expression of several zinc-
finger protein-coding genes (ZFP3, ZNF585B, ZNF320,
ZNF329, ZNF148, ZNF137P, ZNF573, ZNF776 and
ZNF441), as well as the different pattern of expression of
MAP 3 K3, PRKRA, JAK2 and different components of the
STAT family (STAT1, STAT2, STAT3, STAT5A, STAT5B
and STAT6) that have been already defined as MDSC-
associated transcriptional factors [9]. In the metabolism
group, we identified several genes potentially linked to
immunosuppression [31]: fatty acid and lipoprotein
metabolism-related genes, such as CD36, LYPLA1 and
CERS5; energy (ATP) metabolism-associated genes, such
as ATP51C, ATP5G2 and SDHB; glucose metabolism-
associated genes, such as PDK4 and GXYLT1, as well as
hormone and water soluble vitamins metabolism-
associated genes (i.e. HSDL2 and PCCA respectively).
Finally, we identified different genes involved in both
amino acid metabolism, such as ERICH1, GLS, CTSC and
ARG1 and amino acid modifying enzymes, such as NAT2,
UST and OXR1. To understand the depth of cancer-
induced monocyte reprogramming towards MDSCs, we
compared suppressive CD14+ cell gene profiles to gene
signatures of human bone marrow (BM) derived MDSCs
(BM-MDSCs, n = 8 independent donors) obtained by
in vitro differentiation of BM cells in presence of a
cytokine cocktail composed by G-CSF and GM-CSF, as
previously reported [13] (Additional file 1: Figure S5C).
Despite the phenotypic differences and the expected
variances in their isolation and generation, BM-MDSCs
and cancer patient immunosuppressive monocytes dis-
played a shared signature (not-differentially expressed
genes, Fig. 5c) characterized by genes such as PTGS2,
SOCS2, TNF, IDO1, CD38 and ARG1, all related to im-
mune regulation. Interestingly, they also shared expression
levels of AKT3, JAK1, JAK3, STAT1, STAT4, STAT5,
STAT6 and STAT3, suggesting a common signaling
network among these myeloid cells, as well as the same
expression of CFLAR, which we recently reported as an
important candidate for driving the acquisition of the
immunosuppressive program in monocytes [12].
Notably, we identified a cluster of genes that are equally
modulated in both suppressive monocytes and tumor-
educated monocytes (recently described in [32]), suggest-
ing a common tumor-dependent re-programming circuit
(Fig. 5d). Among the most significant genes we identified
SKP2, IRF2 and MCM3, all related to tumor progression
and metastases [33–35]. In agreement with these shared
cues, 5 signaling pathways (MAPK, JAK-STAT, p53,
VEGF and PI3K) that were not significantly different
between immunosuppressive monocytes and tumor-
educated monocytes, were observed; however, we found
other signaling pathways uniquely upregulated in suppres-
sive monocytes NF-κB, TGFβ, TNFα, Hypoxia, TRAIL
and EGFR (Additional file 1: Figure S5D). Collectively,
these data pinpoint suppressive monocytes as a peculiar
subgroup of tumor-educated monocytes.
Finally, we integrated the transcriptome with a
complete miRNAs profiling analysis of suppressive vs.
non-suppressive PDAC CD14+ cells, using the same
samples. The hierarchical clustering highlighted only 18
miRNAs that were differentially expressed between the
two experimental groups (Fig. 5e). Surprisingly, among
the down-regulated miRNAs in the suppressive CD14+
cells (n = 15), we identified mir-17, mir-20a, mir-93, mir-
106 and mir-15a that were reported to directly inhibit
STAT3 [36, 37]. Indeed, these miRNAs are part of the
50 validated miRNAs able to bind the 3′-UTR region of
STAT3 [37]. Therefore, these data allowed us to
hypothesize that gain of suppressive function in MDSC
could be partly dependent on the activation of a STAT3-
dependent gene transcription.
To prove the role of STAT3 among transcriptional
factors driving MDSC function in PDAC, we first
demonstrated an enhanced expression of the Tyr705-
phosphorylated STAT3 (p-STAT3) in suppressive
monocytes (Fig. 6a). Notably, treatment with Stattic, a
specific small-molecule inhibitor of STAT3, significantly
abrogated the suppressive activity of CD14+ cells, while
it had no effects in non-suppressive monocytes, confirm-
ing the role of STAT3-driven program in MDSC-
associated function (Fig. 6b). These results are consistent
with data from Vasquez-Duddel et al. that demonstrated
the therapeutic impact of Stattic on controlling MDSC
function in head and neck squamous cell carcinoma
[14]. Since p-STAT3 is able to bind different sites on the
ARG1 promoter to favor its transcription, we focused
our next analyses on ARG1 expression. We measured
ARG1 protein levels in both suppressive and non-
suppressive CD14+ cells by flow cytometry and immuno-
fluorescence (IF). We demonstrated that CD14+ARG1+
(See figure on previous page.)
Fig. 5 Gene profiling of suppressive CD14+ cells isolated from PDAC patient. a Supervised clustering of suppressive and not suppressive
monocytes arrays using 1119 differentially expressed genes (FDR < 0.05 and absolute fold change > 2). b Clustering of cell cycle, structure,
signaling and metabolism in suppressive- and not suppressive monocytes (absolute fold change > 2; FDR < 20%). c Difference in expression
between suppressive monocytes isolated from PDAC patients and human BM-MDSCs samples for genes in JAK/STAT Signaling Pathway. d Dot
plot of log fold change demonstrating common (yellow plots) or different (purple plots) gene expression modulation between differentially
expressed signature of either tumor-educated or suppressive monocytes to related controls. e miRNAs-expression profile of suppressive and
non-suppressive CD14+ cells isolated from PDAC patients using 19 differentially expressed miRNAs (FDR < 0.05 and absolute fold change > 2)
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cells were significantly increased in cancer patients as
compared to the HDs (Additional file 1: Figure S6A).
However, they were not significantly different among sup-
pressive vs. non-suppressive groups (median value 50.9 ±
3.25 vs. 48.6 ± 4.38; p = 0.76). We then measured the
distribution and intensity of ARG1 by IF and we found a
higher amount of ARG1 in suppressive than in non-
suppressive monocytes (Fig. 6c). Additionally, confocal
analysis showed a different pattern of ARG1 distribution,
with the suppressive CD14+ cells being smaller and with
diffused and less clustered ARG1-containing granules
(Fig. 6d). By Z-stack analysis, suppressive CD14+ cells
shared a significant smaller size (Fig. 6e), suggesting that
immunosuppressive monocytes, that resemble M-MDSCs,
may be clearly distinguished from monocytes present under
steady-state hematopoiesis as small, ARG1+CD14+ cells.
Fig. 6 STAT3/ARG1 signaling is up-regulated in suppressive monocytes. a p-STAT3 detection in suppressive (n = 4) and non-suppressive (n = 4)
PDAC patients’ monocytes was evaluated by flow cytometry. Statistical analysis was performed by ANOVA test. b Functional assay performed (at
1:3 ratio of PBMCs:CD14+ cells) on suppressive (n = 6) and non-suppressive (n = 6) monocytes of PDAC patients. CD14+ cells were treated with
Stattic (5 μM) or DMSO for 30min and, after the treatment, cells were washed three times and plated with T cells. Data are reported as
percentage of CD3+ proliferating cells in three independent experiments. Statistical analysis was performed by ANOVA test. c ARG1 detection in
suppressive (n = 4) and non-suppressive (n = 4) purified PDAC patients’ monocytes was evaluated by flow cytometry. As control, ARG1 expression
in purified monocytes isolated from HDs is shown (n = 5). Statistical analysis was performed by ANOVA test. d Representative images of sorted,
not suppressive or suppressive CD14+ cells obtained from patients with PDAC, stained for DNA (DAPI), ARG1 (green) and CD14 (red). BF = bright
field. e Quantification of cell size by confocal microscopic analysis. Data shown 13 independent measures of each donors (N = 4). Statistical
analysis was performed by ANOVA test
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Discussion
Since the first identification of MDSCs at the end of
1970, both ontogeny and classification of those cells
have been controversial [8]. In fact, while MDSCs share
morphological features with conventional monocytes
and granulocytes, they own the ability to dampen im-
mune responses. Different reports have tried to identify
unique MDSCs markers, but the newly identified subsets
were rarely tested for inhibitory function, consequently
missing the main characteristic to define those cells as
MDSCs. Thus, following the recently published recom-
mendations for MDSC characterization [15], we applied
flow-cytometry technique to discriminate circulating
MDSCs in PDAC patients and tested their ability to
restrain T cell proliferation, in vitro. Interestingly, we
unveiled an overall increased frequency of monocytes
and PMNs in PDAC patients, probably as a consequence
of tumor-induced inflammation. Among these cells, both
M- and PMN-MDSC subsets were expanded in PDAC
patients, both in the blood and tumor tissue, and overall,
they were able to control T cell proliferation. Moreover,
we demonstrated that CD14+ cells isolated from PDAC
patients have a distinctive gene signature as compared to
the monocytes isolated from HD suggesting that, during
cancer progression, monocytes activate specific tran-
scriptional programs that can be, in turn, used as poten-
tial biomarkers. Among patient-derived myeloid cells,
we found CD14+ cells as the most potent myeloid subset
to halt T cell proliferation, in line with previous preclin-
ical data [26]. Notably, the functional assay allowed us to
identify two distinct M-MDSC subgroups, i.e. suppres-
sive and non-suppressive CD14+ cells. This cell discrim-
ination was not connected with changes on the type and
intensity of MDSC-associated markers but relied exclu-
sively on functional suppressive ability mainly mediated
by STAT3 activation. Therefore, functional tests cannot
be considered as an adjunct to MDSC identification but,
on the contrary, have a prioritizing role for definition of
MDSC subsets. However, since standardizing functional
tests among different laboratories might represent a
challenging hurdle [38], we focused our subsequent
efforts in identifying genes and molecular pathways that
can represent clues to their immunosuppressive ability.
Further genetic analysis on M-MDSCs highlighted
several other up-regulated targets linked to different mo-
lecular pathways, including the amino acid metabolism.
In this gene-cluster we identified ARG1, which has been
already associated to MDSC function in both tumor-
bearing mice and cancer patients [39–41]. We recently
reported that ARG1 has a hierarchical role in generating
an immunosuppressive tumor microenvironment among
the L-arginine metabolizing enzymes; indeed, myeloid
cells expressing high levels of the inducible nitric oxide
synthase (iNOS) enzyme (i.e. TNFα- and NO-producing
dendritic cells) actively sustained anti-tumor T cells
response and were counteracted by ARG1 activation in
tumor-associated macrophages [42]. Differently, L-
arginine deprivation, due to ARG1-expressing cells,
strongly compromised both T cell proliferation and
activation [43]. Moreover, ARG1-derived products, i.e.
polyamines, could directly contribute to the generation
of tolerogenic DCs through IDO1 phosphorylation, thus
sustaining the immunosuppressive tumor microenviron-
ment [44]. For the first time, our data demonstrated
that ARG1 is expressed in human cancer-programmed
monocytes, with the suppressive CD14+ monocytes ex-
pressing higher amount of the protein and presenting a
unique pattern of staining, making them trackable from
other circulating monocytes. Notably, circulating mono-
cytes may acquire both ARG1 expression and MDSC-
associated functions after tumor-derived exosomes uptake
suggesting exosomes as tumor-derived cues to reprogram
monocytes into immunosuppressive cells [45, 46]. Thus,
ARG1-targeting approaches, using either ARG1 inhibitors
or small molecules interfering with ARG1 transcription,
such as AT38 or Stattic [14, 47–49], may offer a potential
therapeutic options to the most aggressive form of PDAC.
We think that targeting ARG1, with the new upcoming
generation of engineered MDSC-specific nanoparticles,
will be of great interest for many cancer types to unleash
anti-tumor immunity. To this aim, we recently demon-
strated the ability of newly designed lipid nanocapsules to
vehicle, in vivo, chemotherapeutic agents exclusively to
M-MDSCs, enhancing the therapeutic impact of immuno-
therapy [50].
Only in the recent past, PDAC was deeply interrogated
at the genetic level, therefore revealing the presence of
different molecular subtypes and, among them, an
immune subgroup [51]. Moreover, the presence of a
marked T cell-response against neo-antigen in PDAC
microenvironment was associated to a better patients’
outcome and long term survival [22]. Finally, the recent
efficacy of a combinatorial therapy, based on chemother-
apy and immune checkpoint inhibition, in a mouse
model of PDAC, open up to the development of several
immunotherapeutic approaches that we hope could be
successfully translated into the clinic, in the next
years [52–54]. Of relevance are also recent results on
TGFβ-targeted therapy showing synergism with anti-PD-
L1-based treatment by dampening the tumor immuno-
suppressive microenvironment generated by peri-tumoral
fibroblasts and favoring T cell trafficking to the tumor
[55]. In many cancer patients, the lack of efficacy of
several immunotherapeutic approaches, is related to the
presence of an immunosuppressive network, mainly
composed by MDSCs and macrophages that interferes
with T cell trafficking and activation [24]. In line with
these observations, our analysis of PDAC tumor-
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infiltrating leukocytes confirmed the negative associ-
ation of these cells with T lymphocyte accumulation
and activation. Therefore, we think that an effective
immunotherapeutic approach, in PDAC patients,
should combine the induction or transfer of tumor-
specific T cells with the elimination of immunosup-
pressive cells. To this aim, several strategies might be
explored to generate effective therapies, such as the
use of low-dose chemotherapy, able to abrogate MDSC
proliferation, accumulation and function [56, 57]; or,
specific antibodies that limit myeloid migration into
the tumor, such as monoclonal antibodies to CSF-1 re-
ceptor (CSF-1R), or antibodies to CCR2 and to CXCR4
[58], as well as the use of antibodies able to restrain
tumor-induced inflammation (i.e. anti-IL-6 antibody).
Conclusion
In conclusion, patient-derived M-MDSCs, identified as
suppressive CD14+ cells, showing distinctive cytological
features (a smaller size), functional properties (the ability
to abrogate T cells) and gene signatures (i.e. activation
of STAT3/ARG1 pathway) represent a peculiar branch
within the complexity and heterogeneity of monocyte
population found in tumors. We do not believe that
MDSCs definition is an outdated concept, as recently
postulated [59], but it rather defines a myeloid cell
subset with unique properties, as we demonstrated in
this work. It remains to be determined the tumor-
derived factors that contribute to the development of
this suppressive monocytes and we believe that single-
cell technologies and fate mapping will help to reveal
more information. In this regards, our data open a new
insight in PDAC and in MDSC biology that may lead to
more specific diagnosis and treatment for this lethal
disease.
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